Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prudence Ive

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|July 9, 2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsJoseph C Gathe, Prudence Ive, Robin Wood, et al.
AIDS (London, England)|March 13, 2009
Effect of pulmonary tuberculosis on mortality in patients receiving HAARTDaniel Westreich, Patrick MacPhail, Annelies Van Rie, et al.
AIDS Research and Therapy|April 12, 2018
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South AfricaDenise Evans, Kamban Hirasen, Rebecca Berhanu, et al.
Plos One|December 11, 2013
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trialPrudence Ive, William MacLeod, Nompumelelo Mkumla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2021
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis CoinfectionMichelle A Kendall, Umesh Lalloo, Courtney V Fletcher, et al.
Plos One|July 2, 2016
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-CellsKapil K Saharia, Constantinos Petrovas, Sara Ferrando-Martinez, et al.
Plos One|March 4, 2014
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infectionNoor Dawany, Louise C Showe, Andrew V Kossenkov, et al.
Antiviral Therapy|February 2, 2012
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapyCarole L Wallis, Maria A Papathanasopolous, Matthew Fox, et al.
Plos One|August 23, 2016
Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South AfricaJulia K Rohr, Prudence Ive, C Robert Horsburgh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 10, 2011
Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfectionFrancesca Conradie, Andrea S Foulkes, Prudence Ive, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|July 9, 2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patientsJoseph C Gathe, Prudence Ive, Robin Wood, et al.
AIDS (London, England)|March 13, 2009
Effect of pulmonary tuberculosis on mortality in patients receiving HAARTDaniel Westreich, Patrick MacPhail, Annelies Van Rie, et al.
AIDS Research and Therapy|April 12, 2018
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South AfricaDenise Evans, Kamban Hirasen, Rebecca Berhanu, et al.
Plos One|December 11, 2013
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trialPrudence Ive, William MacLeod, Nompumelelo Mkumla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2021
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis CoinfectionMichelle A Kendall, Umesh Lalloo, Courtney V Fletcher, et al.
Plos One|July 2, 2016
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-CellsKapil K Saharia, Constantinos Petrovas, Sara Ferrando-Martinez, et al.
Plos One|March 4, 2014
Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infectionNoor Dawany, Louise C Showe, Andrew V Kossenkov, et al.
Antiviral Therapy|February 2, 2012
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapyCarole L Wallis, Maria A Papathanasopolous, Matthew Fox, et al.
Plos One|August 23, 2016
Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South AfricaJulia K Rohr, Prudence Ive, C Robert Horsburgh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 10, 2011
Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfectionFrancesca Conradie, Andrea S Foulkes, Prudence Ive, et al.
Pageof 5